keyword
MENU ▼
Read by QxMD icon Read
search

falcon trial

keyword
https://www.readbyqxmd.com/read/28081548/serum-ldh-predicts-benefit-from-bevacizumab-beyond-progression-in-metastatic-colorectal-cancer
#1
Federica Marmorino, Lisa Salvatore, Cecilia Barbara, Giacomo Allegrini, Lorenzo Antonuzzo, Gianluca Masi, Fotios Loupakis, Beatrice Borelli, Silvana Chiara, Maria Chiara Banzi, Emanuela Miraglio, Domenico Amoroso, Francesco Dargenio, Andrea Bonetti, Angelo Martignetti, Myriam Paris, Daniela Tomcikova, Luca Boni, Alfredo Falcone, Chiara Cremolini
BACKGROUND: Different antiangiogenics are currently indicated in the second-line treatment of metastatic colorectal cancer (mCRC), following a first-line bevacizumab-containing treatment. The magnitude of benefit is limited, but no predictors of benefit have been identified. METHODS: A total of 184 mCRC patients progressing to a first-line bevacizumab-containing treatment were randomised in the BEBYP study to continue or not the antiangiogenic in combination with a second-line chemotherapy...
January 12, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28008174/autologous-transplant-vs-oral-chemotherapy-and-lenalidomide-in-newly-diagnosed-young-myeloma-patients-a-pooled-analysis
#2
F Gay, S Oliva, M T Petrucci, V Montefusco, C Conticello, P Musto, L Catalano, A Evangelista, S Spada, P Campbell, R Ria, M Salvini, M Offidani, A M Carella, P Omedé, A M Liberati, R Troia, A M Cafro, A Malfitano, A P Falcone, T Caravita, F Patriarca, A Nagler, A Spencer, R Hajek, A Palumbo, M Boccadoro
In newly diagnosed myeloma patients, upfront autologous transplant (ASCT) prolongs progression-free survival-1 (PFS1) compared with chemotherapy plus lenalidomide (CC+R). Salvage ASCT at first relapse may still effectively rescue patients who did not receive upfront ASCT. To evaluate the long-term benefit of upfront ASCT vs CC+R and the impact of salvage ASCT in patients who received upfront CC+R, we conducted a pooled analysis of 2 phase III trials (RV-MM-209 and EMN-441). Primary endpoints were PFS1, progression-free survival-2 (PFS2), overall survival (OS)...
December 23, 2016: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/27986363/efficacy-of-folfoxiri-plus-bevacizumab-in-liver-limited-metastatic-colorectal-cancer-a-pooled-analysis-of-clinical-studies-by-gruppo-oncologico-del-nord-ovest
#3
Chiara Cremolini, Mariaelena Casagrande, Fotios Loupakis, Giuseppe Aprile, Francesca Bergamo, Gianluca Masi, Roberto Moretto R, Filippo Pietrantonio, Federica Marmorino, Gemma Zucchelli, Gianluca Tomasello, Giuseppe Tonini, Giacomo Allegrini, Cristina Granetto, Laura Ferrari, Lucio Urbani, Umberto Cillo, Pierluigi Pilati, Elisa Sensi, Alessio Pellegrinelli, Massimo Milione, Gabriella Fontanini, Alfredo Falcone
Secondary resection is a chance of cure for a subgroup of metastatic colorectal cancer (mCRC) patients with unresectable liver-limited disease. Medical treatment has a dual goal: to induce tumour shrinkage and to prevent disease relapse. The aims of the present analysis were to assess the efficacy of FOLFOXIRI plus bevacizumab in this setting, and to investigate whether this regimen could revert the poor prognosis of high-risk patients defined by clinical and molecular factors. We performed a pooled analysis of patients with unresectable and liver-limited mCRC, treated with first-line FOLFOXIRI plus bevacizumab in three prospective clinical trials by Gruppo Oncologico del Nord Ovest...
December 13, 2016: European Journal of Cancer
https://www.readbyqxmd.com/read/27943285/annual-research-review-digital-health-interventions-for-children-and-young-people-with-mental-health-problems-a-systematic-and-meta-review
#4
REVIEW
Chris Hollis, Caroline J Falconer, Jennifer L Martin, Craig Whittington, Sarah Stockton, Cris Glazebrook, E Bethan Davies
BACKGROUND: Digital health interventions (DHIs), including computer-assisted therapy, smartphone apps and wearable technologies, are heralded as having enormous potential to improve uptake and accessibility, efficiency, clinical effectiveness and personalisation of mental health interventions. It is generally assumed that DHIs will be preferred by children and young people (CYP) given their ubiquitous digital activity. However, it remains uncertain whether: DHIs for CYP are clinically and cost-effective, CYP prefer DHIs to traditional services, DHIs widen access and how they should be evaluated and adopted by mental health services...
December 10, 2016: Journal of Child Psychology and Psychiatry, and Allied Disciplines
https://www.readbyqxmd.com/read/27908454/fulvestrant-500-mg-versus-anastrozole-1-mg-for-hormone-receptor-positive-advanced-breast-cancer-falcon-an-international-randomised-double-blind-phase-3-trial
#5
John F R Robertson, Igor M Bondarenko, Ekaterina Trishkina, Mikhail Dvorkin, Lawrence Panasci, Alexey Manikhas, Yaroslav Shparyk, Servando Cardona-Huerta, Kwok-Leung Cheung, Manuel Jesus Philco-Salas, Manuel Ruiz-Borrego, Zhimin Shao, Shinzaburo Noguchi, Jacqui Rowbottom, Mary Stuart, Lynda M Grinsted, Mehdi Fazal, Matthew J Ellis
BACKGROUND: Aromatase inhibitors are a standard of care for hormone receptor-positive locally advanced or metastatic breast cancer. We investigated whether the selective oestrogen receptor degrader fulvestrant could improve progression-free survival compared with anastrozole in postmenopausal patients who had not received previous endocrine therapy. METHODS: In this phase 3, randomised, double-blind trial, we recruited eligible patients with histologically confirmed oestrogen receptor-positive or progesterone receptor-positive, or both, locally advanced or metastatic breast cancer from 113 academic hospitals and community centres in 20 countries...
December 17, 2017: Lancet
https://www.readbyqxmd.com/read/27886643/cardiac-safety-of-adjuvant-non-pegylated-liposomal-doxorubicin-combined-with-cyclophosphamide-and-followed-by-paclitaxel-in-older-breast-cancer-patients
#6
Luigi Coltelli, Andrea Fontana, Sara Lucchesi, Laura Ginocchi, Guido Bocci, Mario Filidei, Marco Scalese, Giada Arrighi, Chiara Finale, Lorenzo Marcucci, Orlando Goletti, Barbara Salvadori, Ilaria Ferrarini, Eleonora Bona, Alfredo Falcone, Giacomo Allegrini
PURPOSE: To investigate the cardiac safety of adjuvant Non-Pegylated Liposomal Doxorubicin (NPL-DOX) combined to Cyclophosphamide (CTX) and followed by weekly Paclitaxel, in older patients (≥65 years) with diagnosis of high risk breast cancer. The main end point of this prospective study was the detection of early episodes of symptomatic congestive heart failure (CHF). METHODS: The cardiac function was evaluated by left ventricular ejection fraction (LVEF) measurements with repeated echocardiograms, performed 2 weeks before the beginning of chemotherapy and every 6 months, until 30 months after the study entry; then yearly for at least 5 years...
February 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/27864220/estimating-12-weeks-death-probability-in-patients-with-refractory-metastatic-colorectal-cancer-the-colon-life-nomogram
#7
F Pietrantonio, R Miceli, L Rimassa, S Lonardi, G Aprile, A Mennitto, F Marmorino, S Bozzarelli, L Antonuzzo, E Tamburini, F Morano, D Rossini, F Battaglin, M Baretti, R Berenato, V Formica, S Mosconi, F Petrelli, M Ghidini, F Loupakis, D Spada, S Cinieri, G Beretta, A Falcone, F de Braud, C Cremolini
BACKGROUND: Regorafenib and TAS-102 have recently demonstrated statistically significant survival gains in patients with refractory metastatic colorectal cancer (mCRC). Life expectancy ≥12 weeks was an inclusion criterion in registrative trials, and the identification of proper clinical selection tools for the daily use of these drugs in heavily pre-treated patients is needed to improve the cost-benefit ratio. We aimed at building a nomogram able to predict death probability within 12 weeks from the date of assessment of refractory mCRC...
November 17, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27861516/the-mcme-project-a-randomized-controlled-trial-of-an-sms-based-continuing-medical-education-intervention-for-improving-medical-knowledge-among-vietnamese-community-based-physicians-assistants
#8
Christopher J Gill, Bao Le Ngoc, Nafisa Halim, Ha Nguyen Viet, Anna Larson Williams, Tan Nguyen Van, Marion McNabb, Lien Tran Thi Ngoc, Ariel Falconer, Hai An Phan Ha, Julia Rohr, Hai Hoang, James Michiel, Tam Nguyen Thi Thanh, Liat Bird, Hoang Pham Vu, Mahlet Yeshitla, Nhu Ha Van, Lora Sabin
BACKGROUND: Community health workers (CHWs) provide critical services to underserved populations in low and middle-income countries, but maintaining CHW's clinical knowledge through formal continuing medical education (CME) activities is challenging and rarely occurs. We tested whether a Short Message Service (SMS)-based mobile CME (mCME) intervention could improve medical knowledge among a cadre of Vietnamese CHWs (Community Based Physician's Assistants-CBPAs) who are the leading providers of primary medical care for rural underserved populations...
2016: PloS One
https://www.readbyqxmd.com/read/27857020/surrogate-endpoints-in-second-line-trials-of-targeted-agents-in-metastatic-colorectal-cancer-a-literature-based-systematic-review-and-meta-analysis
#9
Chiara Cremolini, Carlotta Antoniotti, Filippo Pietrantonio, Rosa Berenato, Marco Tampellini, Chiara Baratelli, Lisa Salvatore, Federica Marmorino, Beatrice Borelli, Federico Nichetti, Paolo Bironzo, Cristina Sonetto, Maria Di Bartolomeo, Filippo de Braud, Fotios Loupakis, Alfredo Falcone, Massimo Di Maio
Purpose: To evaluate progression-free survival (PFS) and objective response rate (ORR) as surrogate endpoints of overall survival (OS) in modern clinical trials investigating the efficacy of targeted agents in the second-line treatment of metastatic colorectal cancer (mCRC). Materials and Methods: A systematic search of literature pertaining to randomized phase II and III trials evaluating targeted agents as second-line treatments for mCRC was performed. The strength of the correlation between both PFS and ORR and OS was assessed based on the Pearson's correlation coefficient (R) and the coefficient of determination (R2)...
November 15, 2016: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/27788564/does-positron-emission-tomography-computed-tomography-change-management-in-colorectal-cancer
#10
Rachel Falconer, Saxon Connor, Adrian Balasingam, Tim Eglinton
BACKGROUND: Positron emission tomography/computed tomography (PET/CT) is used pre-operatively in patients with metastatic or recurrent colorectal cancer to identify those who have potentially curative disease. However, a recent randomized trial questioned the added benefit of PET/CT over conventional imaging in patients with liver metastases. The aim of this study was to determine the proportion of patients with colorectal cancer in whom PET/CT altered surgical management, in a single tertiary centre...
October 27, 2016: ANZ Journal of Surgery
https://www.readbyqxmd.com/read/27743922/prognosis-of-patients-with-peritoneal-metastatic-colorectal-cancer-given-systemic-therapy-an-analysis-of-individual-patient-data-from-prospective-randomised-trials-from-the-analysis-and-research-in-cancers-of-the-digestive-system-arcad-database
#11
Jan Franko, Qian Shi, Jeffrey P Meyers, Timothy S Maughan, Richard A Adams, Matthew T Seymour, Leonard Saltz, Cornelis J A Punt, Miriam Koopman, Christophe Tournigand, Niall C Tebbutt, Eduardo Diaz-Rubio, John Souglakos, Alfredo Falcone, Benoist Chibaudel, Volker Heinemann, Joseph Moen, Aimery De Gramont, Daniel J Sargent, Axel Grothey
BACKGROUND: Patients with peritoneal metastatic colorectal cancer have reduced overall survival compared with patients with metastatic colorectal cancer without peritoneal involvement. Here we further investigated the effect of the number and location of metastases in patients receiving first-line systemic chemotherapy. METHODS: We analysed individual patient data for previously untreated patients enrolled in 14 phase 3 randomised trials done between 1997 and 2008...
December 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27703757/embodying-self-compassion-within-virtual-reality-and-its-effects-on-patients-with-depression
#12
Caroline J Falconer, Aitor Rovira, John A King, Paul Gilbert, Angus Antley, Pasco Fearon, Neil Ralph, Mel Slater, Chris R Brewin
BACKGROUND: Self-criticism is a ubiquitous feature of psychopathology and can be combatted by increasing levels of self-compassion. However, some patients are resistant to self-compassion. AIMS: To investigate whether the effects of self-identification with virtual bodies within immersive virtual reality could be exploited to increase self-compassion in patients with depression. METHOD: We developed an 8-minute scenario in which 15 patients practised delivering compassion in one virtual body and then experienced receiving it from themselves in another virtual body...
January 2016: BJPsych Open
https://www.readbyqxmd.com/read/27660192/adjuvant-capecitabine-plus-bevacizumab-versus-capecitabine-alone-in-patients-with-colorectal-cancer-quasar-2-an-open-label-randomised-phase-3-trial
#13
Rachel S Kerr, Sharon Love, Eva Segelov, Elaine Johnstone, Beverly Falcon, Peter Hewett, Andrew Weaver, David Church, Claire Scudder, Sarah Pearson, Patrick Julier, Francesco Pezzella, Ian Tomlinson, Enric Domingo, David J Kerr
BACKGROUND: Antiangiogenic agents have established efficacy in the treatment of metastatic colorectal cancer. We investigated whether bevacizumab could improve disease-free survival in the adjuvant setting after resection of the primary tumour. METHODS: For the open-label, randomised, controlled QUASAR 2 trial, which was done at 170 hospitals in seven countries, we recruited patients aged 18 years or older with WHO performance status scores of 0 or 1 who had undergone potentially curative surgery for histologically proven stage III or high-risk stage II colorectal cancer...
November 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27656206/treatment-with-antiangiogenic-drugs-in-multiple-lines-in-patients-with-metastatic-colorectal-cancer-meta-analysis-of-randomized-trials
#14
REVIEW
R-D Hofheinz, U Ronellenfitsch, S Kubicka, A Falcone, I Burkholder, U T Hacker
Background. In metastatic colorectal cancer (mCRC), continuing antiangiogenic drugs beyond progression might provide clinical benefit. We synthesized the available evidence in a meta-analysis. Patients and Methods. We conducted a meta-analysis of studies investigating the use of antiangiogenic drugs beyond progression. Eligible studies were randomized phase II/III trials. Primary endpoints were overall survival (OS) and progression-free survival (PFS). Secondary endpoints were the impact of continuing antiangiogenic drugs (i) in subgroups, (ii) in different types of compounds targeting the VEGF-axis (monoclonal antibodies versus tyrosine kinase inhibitors), and (iii) on remission rates and prevention of progression...
2016: Gastroenterology Research and Practice
https://www.readbyqxmd.com/read/27635998/can-brain-games-help-smokers-quit-results-of-a-randomized-clinical-trial
#15
James Loughead, Mary Falcone, E Paul Wileyto, Benjamin Albelda, Janet Audrain-McGovern, Wen Cao, Matthew M Kurtz, Ruben C Gur, Caryn Lerman
BACKGROUND AND AIMS: Deficits in cognitive function are observed during nicotine withdrawal and present a challenge to successful smoking cessation. This clinical trial evaluated a cognitive exercise training (CT) program to improve smoking cessation rates. METHODS: Adult treatment-seeking smokers (n=213) were randomized to receive nicotine patch therapy and 12 weeks of either computerized CT or computerized relaxation (control) training. Smoking status was biochemically verified at the end of treatment and 6-month follow-up...
November 1, 2016: Drug and Alcohol Dependence
https://www.readbyqxmd.com/read/27610011/folfirinox-and-translational-studies-towards-personalized-therapy-in-pancreatic-cancer
#16
REVIEW
Chiara Caparello, Laura L Meijer, Ingrid Garajova, Alfredo Falcone, Tessa Y Le Large, Niccola Funel, Geert Kazemier, Godefridus J Peters, Enrico Vasile, Elisa Giovannetti
Pancreatic cancer is an extremely aggressive disease; although progress has been made in the last few years, the prognosis of these patients remains dismal. FOLFIRINOX is now considered a standard treatment in first-line setting, since it demonstrated an improved overall and progression-free survival vs gemcitabine alone. However, the enthusiasm over the benefit of this three-drug regimen is tempered by the associated increased toxicity profile, and many efforts have been made to improve the feasibility of this schedule...
August 21, 2016: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/27607877/deceased-donor-uterine-transplantation-innovation-and-adaptation
#17
Rebecca L Flyckt, Ruth M Farrell, Uma C Perni, Andreas G Tzakis, Tommaso Falcone
This commentary endeavors to share our practical experience in developing and implementing the first uterine transplant clinical trial in the United States. Uterine transplant is a promising novel treatment for uterine factor infertility. After reported successful live births after uterine transplant in Sweden, research teams around the world are either embarking on or are considering the development of uterine transplant protocols. Our observations on the applied rather than theoretical aspects of uterine transplantation research in human subjects are detailed in this article...
October 2016: Obstetrics and Gynecology
https://www.readbyqxmd.com/read/27566635/near-infrared-fluorescence-cholangiography-assisted-laparoscopic-cholecystectomy-versus-conventional-laparoscopic-cholecystectomy-falcon-trial-study-protocol-for-a-multicentre-randomised-controlled-trial
#18
Jacqueline van den Bos, Rutger M Schols, Misha D Luyer, Ronald M van Dam, Alexander L Vahrmeijer, Wilhelmus J Meijerink, Paul D Gobardhan, Gooitzen M van Dam, Nicole D Bouvy, Laurents P S Stassen
INTRODUCTION: Misidentification of the extrahepatic bile duct anatomy during laparoscopic cholecystectomy (LC) is the main cause of bile duct injury. Easier intraoperative recognition of the biliary anatomy may be accomplished by using near-infrared fluorescence (NIRF) imaging after an intravenous injection of indocyanine green (ICG). Promising results were reported for successful intraoperative identification of the extrahepatic bile ducts compared to conventional laparoscopic imaging...
August 26, 2016: BMJ Open
https://www.readbyqxmd.com/read/27557783/clinical-pharmacodynamic-and-pharmacokinetic-results-of-a-prospective-phase-ii-study-on-oral-metronomic-vinorelbine-and-dexamethasone-in-castration-resistant-prostate-cancer-patients
#19
Teresa Di Desidero, Lisa Derosa, Luca Galli, Paola Orlandi, Andrea Fontana, Anna Fioravanti, Riccardo Marconcini, Mario Giorgi, Beatrice Campi, Alessandro Saba, Sara Lucchesi, Renato Felipetto, Romano Danesi, Giulio Francia, Giacomo Allegrini, Alfredo Falcone, Guido Bocci
The aim of the present study was to evaluate clinical activity, and the pharmacodynamic and pharmacokinetic profiles, of oral metronomic vinorelbine (VNR) plus dexamethasone (DEX) in metastatic castration-resistant prostate cancer (mCRPC) patients. Fourty-one patients (92 % chemotherapy-resistant) received 30 mg/day VNR p.o. thrice a week plus 1 mg/day DEX p.o. until disease progression. Plasma soluble B cell antigen 7 homolog 3 (sB7-H3), vascular endothelial growth factor (VEGF), and thrombospondin-1 (TSP-1), were measured by ELISA...
December 2016: Investigational New Drugs
https://www.readbyqxmd.com/read/27545815/role-of-fulvestrant-in-the-treatment-of-postmenopausal-metastatic-breast-cancer-patients
#20
Francesca Poggio, Matteo Lambertini, Eva Blondeaux, Marina Vaglica, Alessia Levaggi, Paolo Pronzato, Lucia Del Mastro
INTRODUCTION: Endocrine therapy is considered the cornerstone treatment for postmenopausal women with hormone-receptor positive metastatic breast cancer. Fulvestrant is a selective estrogen receptor down-regulator (SERD) with demonstrated activity and efficacy in the treatment of these patients. AREAS COVERED: The present manuscript aims to review the mechanism of action of fulvestrant, the clinical efficacy data with the use of different dosages and schedules, and finally its role in association with other medications...
September 2016: Expert Review of Clinical Pharmacology
keyword
keyword
120390
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"